[
    [
        {
            "time": "",
            "orginal_text": "鼓励挑战专利，支持首仿！正大天晴、东阳光、恒瑞、齐鲁、人福等头部企业百舸争流",
            "features": {
                "keywords": [
                    "首仿",
                    "正大天晴",
                    "东阳光",
                    "恒瑞",
                    "齐鲁",
                    "人福",
                    "头部企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "鼓励挑战专利，支持首仿！正大天晴、东阳光、恒瑞、齐鲁、人福等头部企业百舸争流",
            "scores": {
                "News_content": "鼓励挑战专利，支持首仿！正大天晴、东阳光、恒瑞、齐鲁、人福等头部企业百舸争流",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "抗癌药百泽安第八项适应症受理 PD-1竞速下创新药巨头离盈利还有多远？",
            "features": {
                "keywords": [
                    "抗癌药",
                    "百泽安",
                    "PD-1",
                    "适应症",
                    "创新药",
                    "盈利"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "抗癌药百泽安第八项适应症受理 PD-1竞速下创新药巨头离盈利还有多远？",
            "scores": {
                "News_content": "抗癌药百泽安第八项适应症受理 PD-1竞速下创新药巨头离盈利还有多远？",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "遭遇集采“闷棍”，恒瑞进军冷门品种",
            "features": {
                "keywords": [
                    "集采",
                    "恒瑞",
                    "冷门品种"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "遭遇集采“闷棍”，恒瑞进军冷门品种",
            "scores": {
                "News_content": "遭遇集采“闷棍”，恒瑞进军冷门品种",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "集采常态化加速行业洗牌 药企抢占新药与非医保赛道",
            "features": {
                "keywords": [
                    "集采",
                    "常态化",
                    "行业洗牌",
                    "新药",
                    "非医保"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "集采常态化加速行业洗牌 药企抢占新药与非医保赛道",
            "scores": {
                "News_content": "集采常态化加速行业洗牌 药企抢占新药与非医保赛道",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-07-07",
            "orginal_text": "A股融资融券日报：两融余额增加101.08亿元（7月7日）",
            "features": {
                "keywords": [
                    "两融余额",
                    "A股",
                    "融资融券"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "A股融资融券日报：两融余额增加101.08亿元（7月7日）",
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加101.08亿元（7月7日）",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "医药创新长期高景气，看多龙头公司",
            "features": {
                "keywords": [
                    "医药创新",
                    "高景气",
                    "龙头公司"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药创新长期高景气，看多龙头公司",
            "scores": {
                "News_content": "医药创新长期高景气，看多龙头公司",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "集采常态化加速行业洗牌，药企转型抢占新药与非医保赛道",
            "features": {
                "keywords": [
                    "集采",
                    "常态化",
                    "行业洗牌",
                    "转型",
                    "新药",
                    "非医保"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "集采常态化加速行业洗牌，药企转型抢占新药与非医保赛道",
            "scores": {
                "News_content": "集采常态化加速行业洗牌，药企转型抢占新药与非医保赛道",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]